Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A1 | P13866 | 2/20 | 0.46 |
| ▸ | SLC5A2 | P31639 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | TYR | P14679 | 1/20 | 0.46 |
| ▸ | APP | P05067 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 4/20 | 0.43 |
| ▸ | CA9 | Q16790 | 4/20 | 0.43 |
| ▸ | CA1 | P00915 | 3/20 | 0.43 |
| ▸ | CA2 | P00918 | 2/20 | 0.43 |
| ▸ | TLR4 | O00206 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10103009 | 1.00 | SLC5A1 (0.46) | SLC5A1SLC5A2TDP1TYRAPP | |
| SCHEMBL10103013 | 0.89 | APP (0.56) | SLC5A1SLC5A2TDP1TYRAPP | |
| SCHEMBL10103048 | 0.89 | APP (0.56) | SLC5A1SLC5A2TDP1TYRAPP | |
| SCHEMBL10102899 | 0.85 | SLC5A1 (0.43) | SLC5A1SLC5A2TDP1TYRAPP | |
| SCHEMBL10108861 | 0.85 | SLC5A1 (0.43) | SLC5A1SLC5A2TDP1TYRAPP | |
| SCHEMBL10102861 | 0.85 | SLC5A1 (0.43) | SLC5A1SLC5A2TDP1TYRAPP | |
| SCHEMBL10103041 | 0.83 | TYR (0.48) | SLC5A1SLC5A2TDP1TYR | |
| SCHEMBL10103011 | 0.83 | TYR (0.48) | SLC5A1SLC5A2TDP1TYR | |
| SCHEMBL21681151 | 0.81 | TLR4 (0.49) | TDP1TYRTLR4 | |
| SCHEMBL20521198 | 0.81 | TLR4 (0.49) | TDP1TYRTLR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120022012-A1 | Glycosylated Acetaminophen Pro-Drug Analogs | NuTek Pharma Ltd. | 2012-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022012-A1 | Glycosylated Acetaminophen Pro-Drug Analogs | UGT1A3, GCG, UGT1A1 | SLC5A1 62/4885SLC5A2 79/4885TDP1 2646/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.